Press release BoxID: 267536 (Roche Diagnostics Deutschland GmbH)
  • Roche Diagnostics Deutschland GmbH
  • Sandhofer Str. 116
  • 68305 Mannheim
  • Contact person
  • Kary Staples
  • +1 (608) 218-7623

Roche NimbleGen Introduces the MS 200 Microarray Scanner, Unleashing the Full Potential of NimbleGen Arrays

(PresseBox) (Madison, WI, USA, ) Roche NimbleGen introduces a new high-resolution scanning instrument, the NimbleGen MS 200 Microarray Scanner. The MS 200 is the first scanner optimized to reveal the full potential and capture the complete picture from all NimbleGen DNA microarrays. This offering completes the NimbleGen DNA Microarray processing family, comprised of a high-resolution suite of innovative microarray technology products, supplies, equipment, and instrumentation as well as software for data analysis.

The highly sensitive scanner reproducibly acquires two-color fluorescent array image data down to 2 micron pixel resolution and generates high-quality image files for subsequent data analysis. To satisfy today's high-throughput requirements and make high throughput genomics a reality, the MS 200 offers several key features for a completely automated system allowing for walk away scanning and overnight runs. These features include a slide magazine for automated loading of up to 48 microarrays (for processing of up to 576 samples in a single run with NimbleGen multiplex arrays), advanced dynamic autofocus for a clear picture of your data, and auto gain for a bright scan every time. Additionally, the high signal-to-noise, internal calibration, an integrated barcode reader, and ozone reduction features ensure high data quality and confidence with every scan.

With the addition of the MS 200 Microarray Scanner, Roche NimbleGen now presents a complete, optimized workflow for NimbleGen DNA microarrays used for comparative genomic hybridization (CGH), Chromatin ImmunoPrecipitation-on-chip (ChIP-chip), DNA methylation, and Gene Expression. This optimized workflow encompasses high-density NimbleGen arrays, 4-bay and 12-bay hybridization systems, the Microarray Dryer, the MS 200 Microarray Scanner, NimbleScan and SignalMap software, and a comprehensive range of kits and consumables.

According to Roche NimbleGen CEO, Gerd Maass, "With the addition of the MS 200 scanner, Roche NimbleGen now provides a comprehensive set of microarray processing workflow tools that are optimized for all current high-density NimbleGen arrays and will be compatible with tomorrow's next-generation NimbleGen arrays. The MS 200 provides researchers doing disease-related studies, such as cytogenetics laboratories, with powerful scanning resolution down to 2 micron and high signal to noise for enhanced data quality and confidence in their results every time.

Roche NimbleGen is a leading innovator, manufacturer, and supplier of a proprietary suite of DNA microarrays, consumables, instruments and services. Roche NimbleGen produces high-density arrays of long oligonucleotide probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The enhanced performance is made possible by Roche NimbleGen's proprietary Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesize long oligonucleotide, high-density DNA microarrays with extreme flexibility. For more information about Roche NimbleGen, please visit the company's website at

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

NIMBLEGEN is a trademark of Roche.

Other brands or product names are trademarks of their respective holders.